Evidence map›Paper›PMID 35111450›Full record

ArticleCureus2021

Clinical Presentation, Management, and Outcome in Patients With Myasthenia Gravis: A Retrospective Study From Two Tertiary Care Centers in Saudi Arabia.

Hussein Algahtani, Bader Shirah, Ali Alshehri, Abdulaziz N Al Hassani, Hosam H Binseddeq, Rayan M Mukhtar, Bashar Saleh, Jamal A Taj

Abstract read
In one paragraph

Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hussein AlgahtaniDepartment of Medicine, Neurology Section, King Abdulaziz Medical City, Jeddah, SAU.
Bader ShirahDepartment of Neuroscience, King Faisal Specialist Hospital and Research Centre, Jeddah, SAU.
Ali AlshehriNeuromuscular Integrated Practice Unit, Neuroscience Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, SAU.
Abdulaziz N Al HassaniCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, SAU.
Hosam H BinseddeqCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, SAU.
Rayan M MukhtarCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, SAU.
Bashar SalehCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, SAU.
Jamal A TajCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, SAU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionA limited number of research studies were published to delineate the clinical pattern of myasthenia gravis in Saudi Arabia. This paper is an attempt to describe some of the clinical aspects related to this disease in two large centers from two main cities in Saudi Arabia.

methodsA retrospective multi-center observational study of patients diagnosed with myasthenia gravis was conducted. The study setting was King Abdulaziz Medical City in Jeddah and Riyadh, Saudi Arabia. The study period was 12 years, starting from January 2007 to May 2019.

resultsA total of 144 patients were included in this study (60 males and 84 females). The most common symptoms at diagnosis were ocular symptoms in 118 patients (81.9%), diplopia in 84 patients (58.3%), and/or blurred vision in 30 patients (20.8%). The majority had positive anti-acetylcholine receptor antibodies (72.2%). Pyridostigmine was the most prescribed medication for 136 patients (94.4%). Immunosuppressive medications were prescribed for 114 patients (79.2%). Around 40% of patients had exacerbations, and approximately 20% were admitted to the ICU. Thymectomy was performed for 97 patients (67.4%).

conclusionThe present study indicates that the clinical presentation and management of myasthenia gravis remained the same in the last few years despite the introduction of new modalities of diagnosis such as the anti-muscle-specific kinase (anti-MuSK) and other autoantibodies tests. Furthermore, we observed that the number of exacerbations and ICU admission were high, which may indicate inadequate therapy. We are stressing the need for establishing specialized neuromuscular clinics with neurologists trained in neurophysiology to improve the diagnostic accuracy and outcomes for patients with myasthenia gravis.

Indexed as

clinical featuresclinical patterndisease coursemyasthenia gravisthymectomy

Identifiers

PMID35111450
PMCPMC8794400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.